Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 1-Year Low – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s share price reached a new 52-week low on Friday . The stock traded as low as $26.03 and last traded at $26.54, with a volume of 86040 shares traded. The stock had previously closed at $27.71.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Scotiabank upped their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Trading Down 8.1 %

The company’s fifty day simple moving average is $32.73 and its 200 day simple moving average is $40.40. The stock has a market capitalization of $1.46 billion, a P/E ratio of 2.23 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth about $33,000. GF Fund Management CO. LTD. bought a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $39,000. Wingate Wealth Advisors Inc. purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth approximately $53,000. Sterling Capital Management LLC grew its position in Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 1,587 shares during the last quarter. Finally, KBC Group NV grew its position in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.